Stockscreener 앱 받기
30.01
0.37%
-0.11
시장 영업 전:
29.91
-0.10
-0.33%
전일 마감가:
$30.12
열려 있는:
$30.14
하루 거래량:
562.14K
Relative Volume:
0.83
시가총액:
$1.87B
수익:
$32.08M
순이익/손실:
$-169.77M
주가수익비율:
-10.56
EPS:
-2.8418
순현금흐름:
$-147.70M
1주 성능:
-2.91%
1개월 성능:
-8.95%
6개월 성능:
-2.79%
1년 성능:
+175.83%
1일 변동 폭
$29.55
$31.07
1주일 범위
$28.51
$31.07
52주 변동 폭
$10.90
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
30.01 | 1.88B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-05 | 개시 | Guggenheim | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options - Stock Titan
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Stoke Therapeutics (STOK) director granted 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike - Stock Titan
Stoke Therapeutics (STOK) director granted options to buy 17,786 shares - Stock Titan
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Stoke Therapeutics Stockholders Approve Directors and Governance Items - TipRanks
Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors - Stock Titan
STOK: Lead therapy delivers durable seizure and cognitive benefits, with pivotal data due mid-2027 - TradingView
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stoke Therapeutics Advances Dravet Syndrome Clinical Trials Following Positive Results - asatunews.co.id
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates - Yahoo Finance
Stoke Therapeutics (STOK) Pulls Back: Support Test Looms After 2.21% DeclineMoving Average Crossovers - The Legal Advocate
STOK Analyst Consensus - Investing.com Australia
STOK Corporate Insider Activity - Investing.com Australia
Stoke Therapeutics to Present at Upcoming Investor Conferences in June - Business Wire
Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Lower: Mixed Signals Near Key ResistanceInstitutional Sentiment - The Legal Advocate
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Nathan Lee Starts New Role as Vice President, Commercial Manufacturing at Stoke Therapeutics - hrtoday.in
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed - simplywall.st
Zorevunersen tied to long-term benefits in Dravet syndrome - Dravet Syndrome News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 - BioSpace
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake - Stock Titan
Technical Reactions to STOK Trends in Macro Strategies - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK) - Stock Titan
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK) - Stock Titan
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake - Stock Titan
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK) - Stock Titan
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK) - Stock Titan
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate - Moomoo
Stoke Therapeutics Q1 earnings call highlights - MSN
HC Wainwright Analysts Boost Earnings Estimates for STOK - MarketBeat
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance - MSN
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Progyny (PGNY) - The Globe and Mail
Stoke Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-05-11 - Seeking Alpha
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research - MarketBeat
STOK Reiterates by BTIG -- Price Target Maintained at $39.00 - GuruFocus
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60 - Moomoo
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Guardant Health (GH) and Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Stoke Therapeutics Inc 주식 (STOK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
May 01 '26 |
Sale |
32.79 |
2,243 |
73,548 |
36,621 |
1.13%
3.22%
자본화:
|
볼륨(24시간):